HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Business News: Biofarma Gets New PE Owners; Montefarmaco Strikes Ipsen Deal; Stada Expands Production Network

Executive Summary

Round-up of the latest European consumer health market news: Private-equity firm Ardian acquires Italian supplements and cosmetics manufacturer Biofarma; Montefarmaco OTC strikes deal with Ipsen for GI lines; and Stada expands its production network with new Romania site.

You may also be interested in...



EU Business News: Orkla Acquires Healthspan, Bayer Invests Locally, Ipsen Targets Baltics

A round-up of the latest European consumer health business news: Norway's Orkla strengthens its supplements offering with acquisition of UK's Healthspan; Bayer makes investment commitment to German Consumer Health operation; and Ipsen strikes a deal to promote brands in the Baltics.

EU Business News: GSK Consumer Gets New Name, Navamedic Strikes Ipsen Deal, Enzymatica Optimistic After Tough Year

Round-up of the latest European consumer health business news: GSK reveals name for standalone consumer health business will be Haleon; Norways' Navamedic strikes a distribution deal with Ipsen for select GI OTC products; and Sweden's Enzymatica hopeful that changed consumer behaviors will help its sales rebound in 2022.

Sun Pharma Grows OTC Offering In Romania With Uractiv Brand Acquisition

India's Sun Pharma has expanded the portfolio of its Romanian subsidiary Terapia with the acquisition of the Uractiv urinary tract health brand.

Topics

UsernamePublicRestriction

Register

RS152152

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel